Therapeutics Development and Supply, Analytical Development, Janssen Biologics BV., Einsteinweg 101, Leiden 2333 CB, the Netherlands.
Therapeutics Development and Supply, Analytical Development, Janssen Biologics BV., Einsteinweg 101, Leiden 2333 CB, the Netherlands.
J Pharm Biomed Anal. 2024 Aug 1;245:116145. doi: 10.1016/j.jpba.2024.116145. Epub 2024 Apr 10.
Non-ionic surfactants such as Polysorbate 20/ 80 (PS20/ PS80), are commonly used in protein drug formulations to increase protein stability by protecting against interfacial stress and surface absorption. Polysorbate is susceptible to degradation which can impact product stability, leading to the formation of sub-visible and/or visible particles in the drug product during its shelf-life, affecting patient safety and efficacy. Therefore, it is important to monitor polysorbate concentration in drug product formulations of biotherapeutic drugs. The common method for measuring polysorbate concentration in drug product formulations uses mixed mode ion exchange reversed phase HPLC (MAX) coupled to evaporative light scattering detection (ELSD). However, high protein concentration can adversely impact method performance due to high sample viscosity, gel formation, column clogging, interfering peaks and loss of accuracy. To overcome this, a new method was developed based on EDTA mediated ethanol protein precipitation (EDTA/EtOH). This method was successfully implemented for the analysis of polysorbate in antibody formulations with wide range of protein concentration (10-250 mg/mL).
非离子表面活性剂,如聚山梨酯 20/80(PS20/PS80),常用于蛋白质药物制剂中,通过防止界面应力和表面吸附来增加蛋白质稳定性。聚山梨酯容易降解,这可能会影响产品稳定性,导致药物在货架期内形成亚可见和/或可见颗粒,从而影响患者的安全性和疗效。因此,监测生物治疗药物药物制剂中聚山梨酯的浓度非常重要。测量药物制剂中聚山梨酯浓度的常用方法是使用混合模式离子交换反相 HPLC(MAX)与蒸发光散射检测(ELSD)相结合。然而,由于高蛋白质浓度会导致样品粘度高、凝胶形成、柱子堵塞、干扰峰和准确性降低,因此会对方法性能产生不利影响。为了克服这一问题,开发了一种基于 EDTA 介导的乙醇蛋白沉淀(EDTA/EtOH)的新方法。该方法已成功用于分析蛋白质浓度范围较宽(10-250mg/ml)的抗体制剂中的聚山梨酯。